Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 1.00 |
| ▸ | TPST2 | O60704 | 2/20 | 0.46 |
| ▸ | SULT1E1 | P49888 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295389 | 0.88 | PTPN1 (0.78) | PTPN1TPST2SULT1E1MEN1POLB | |
| SCHEMBL29955707 | 0.84 | PTPN1 (0.72) | PTPN1TPST2SULT1E1MEN1POLB | |
| SCHEMBL29956932 | 0.81 | PTPN1 (0.68) | PTPN1TPST2SULT1E1MEN1POLB | |
| SCHEMBL28262152 | 0.79 | PTPN1 (0.65) | PTPN1TPST2SULT1E1MEN1POLB | |
| SCHEMBL29956402 | 0.79 | PTPN1 (0.65) | PTPN1TPST2SULT1E1MEN1POLB | |
| SCHEMBL7026584 | 0.78 | PTPN1 (0.64) | PTPN1TPST2SULT1E1POLBKMT2A | |
| SCHEMBL30307601 | 0.77 | PTPN1 (0.62) | PTPN1MEN1POLBKMT2AMAOA | |
| SCHEMBL8171800 | 0.76 | PTPN1 (0.61) | PTPN1TPST2SULT1E1MEN1KMT2A | |
| SCHEMBL5363245 | 0.73 | PTPN1 (1.00) | PTPN1POLBKMT2AMAOAMAOB | |
| SCHEMBL11541084 | 0.73 | PTPN1 (0.58) | PTPN1TPST2SULT1E1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEMICAL LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4576305-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-06-25 | — | — | EP | disclosed |
| CN-120153509-A | Nonaqueous electrolyte for lithium secondary battery and lithium secondary battery comprising same | 株式会社LG化学 | 2025-06-13 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20120316192-A1 | SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2532664-A1 | Substituted indolo [2,3-a] quinolizines in the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20040063157-A1 | Pharmacophore recombination for the identification of small molecule drug lead compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-01 | — | — | US | disclosed |
| US-20020115107-A1 | Pharmacophore recombination for the identification of small molecule drug lead compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-08-22 | — | — | US | disclosed |
| US-6344334-B1 | DETECTION OF LEAD DRUG LIGANDS SUCH AS PROTEINS, NUCLEIC ACIDS OR SACCHARIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-05 | — | — | US | disclosed |
| US-6344330-B1 | DETECTION OF LEAD DRUG LIGANDS SUCH AS PROTEINS, NUCLEIC ACIDS OR SACCHARIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-05 | — | — | US | disclosed |
| EP-1066522-A1 | PHARMACOPHORE RECOMBINATION FOR THE IDENTIFICATION OF SMALL MOLECULE DRUG LEAD COMPOUNDS | The Regents of the University of California (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999049314-A9 | PHARMACOPHORE RECOMBINATION FOR THE IDENTIFICATION OF SMALL MOLECULE DRUG LEAD COMPOUNDS | UNIV CALIFORNIA (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999049314-A1 | PHARMACOPHORE RECOMBINATION FOR THE IDENTIFICATION OF SMALL MOLECULE DRUG LEAD COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-30 | — | — | WO | disclosed |
| US-4320133-A | Penicillins and their antibacterial use | SANDOZ LTD. (CH) | 1982-03-16 | — | — | US | disclosed |
| EP-0003115-A1 | Penicillins, per se and for use as antibacterially active antibiotics and their production | SANDOZ AG (CH) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316192-A1 | SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES | BOD1L1, ACIN1, CDC25C | PTPN1 1437/4885TPST2 598/4885SULT1E1 1090/4885 |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | PTPN1 770/4885TPST2 2142/4885SULT1E1 961/4885 |
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | CLCN2, CLIC1, RER1 | PTPN1 107/4885TPST2 4116/4885SULT1E1 1061/4885 |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | PTPN1 770/4885TPST2 2142/4885SULT1E1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.